Agreed bro...and considering IPCI didn't lose ANY market share of their already commercialized 15mg and 30mg FocalinXR sales a full calendar year after their 180 day exclusivity window passed...it's a mockery that the market currently has IPCI priced for total and complete failure when one considers the timeline on the rest of their pending ANDA approvals alone...to say nothing about the timeframe on their potential best-in-class Rexista NDA!!!
The beauty of this ongoing delay game bs which is far outside of IPCI's control I might add...is that when the street does finally begin to price and reward IPCI properly these dog days are going to be looked back upon as the golden loading zone.
It's not how many obstacles/hurdles IPCI and their current crop of shareholders have been facing over the past 21 months that matters...all that matters is what the street's going to do when all the pent up catalysts in IPCI's pipeline finally start to hit right! Then all these frustrating dog days will come full circle and we will finally begin to be rewarded for our vision...and especially our fortitude cheers!
News 
Market Data 
Discover 
AI
